David Berry joined Flagship in 2005 while completing his M.D. from Harvard Medical School. He was also awarded, in 2005, a Ph.D. through the MIT Biological Engineering Division, where he studied drug delivery and sugar biology with Professors Ram Sasisekharan and Robert Langer. David also did his undergraduate work at MIT, graduating in 2000 Phi Beta Kappa and Sigma Xi, with a degree in brain and cognitive sciences. He was named as a member of the MIT Corporation - its Board of Trustees - in 2006, and to the MIT Enterprise Forum Global Board in 2010. David's work has led to 14 peer-reviewed publications, over 40 patents and applications, as well as over 35 awards and honors including the prestigious Lemelson-MIT Student Prize for invention and innovation in 2005. David was also named as the Innovator of the Year under the age of 35 by Technology Review in 2007.
At Flagship, David focuses on investing in and founding early-stage life science and sustainability ventures. He is a founder of Flagship portfolio companies LS9, Joule Unlimited, Theracrine, Eleven Biotherapeutics, Essentient, among others. David currently serves as founding CEO at Theracrine and Essentient, and previously served as founding CEO of Joule. He was a Board member of Flagship portfolio company CGI Pharmaceuticals (acquired by Gilead in 2010), and currently serves as a director of Joule, Theracrine, Eleven, and Essentient.